|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:adjuvantType
|
liposome-based
|
|
gptkbp:alternativeTo
|
gptkb:Zostavax
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:J07BK02
|
|
gptkbp:brand
|
gptkb:Shingrix
|
|
gptkbp:CDCRecommendation
|
adults 50 years and older
immunocompromised adults 19 years and older
|
|
gptkbp:contains
|
gptkb:AS01B_adjuvant
recombinant varicella zoster virus glycoprotein E
|
|
gptkbp:contraindication
|
severe allergic reaction to any component
|
|
gptkbp:dosingSchedule
|
two doses, 2 to 6 months apart
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shingrix vaccine
|
|
gptkbp:indication
|
adults aged 50 years and older
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:notLiveVaccine
|
true
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:protectionDuration
|
at least 7 years
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
pain at injection site
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:usedFor
|
prevention of herpes zoster
prevention of shingles
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:AS01
|
|
gptkbp:bfsLayer
|
6
|